Company intelligence / Profile preview

Nelson Biotechnologies

Flagstaff, Arizona, United States

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Nelson Biotechnologies specializes in the development and commercialization of novel chemistries for labeling and modifying synthetic oligonucleotides. Their patented serinol scaffold technology mimics the internucleotide phosphate backbone, offering advantages in stability and versatility for DNA/RNA labeling applications. Specialty reagents using this technology are commercially available through Glen Research Corporation.

Modalities: Synthetic oligonucleotide
Industry: Non-Drug Biotech

Partnerships

Glen Research Corporation (commercialization partner for specialty reagents)Patent collaboration with Glen Research

Beyond the preview

Go deeper on Nelson Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nelson Biotechnologies.

Explore the full profile